Skip to main content

Table 5 Pulmonary vascular properties of vasoactive agents

From: Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review

  CI PVR SVR PVR/SVR Tachycardia Renala/metabolic
Vasopressors     Dose related   
   NE + + ++ +/- + Lactic acidosis
   PHE - ++ + + - -
   Low-dose AVP +/- +/- ++ - - Diuresis ++
Inotropes       
   Dobutamine ++ - - - +  
   < 5 μg/kg/min       
   Dopamine + +/- + + ++ Natriuresis
   Epinephrine ++ - ++ - ++ Lactic acidosis
Inodilators       
   PDE IIIs ++ - - - +/- -
   Levosimendan ++ - - - - -
  1. AVP, arginine vasopressin; NE, norepinephrine; PDE IIIs, phosphodiesterase inhibitors; PHE, phenylephrine. aRenal blood flow is likely to improve with increased cardiac output and systemic blood pressure with all agents.